Company: APM
Filing Date: 2025-07-22
Form Type: 6-K
Source: 0001213900-25-066642
Chunk: 13

Company: Aptorum Group Ltd
Filing Date: 2025-07-22
Form: 6-K
Chunk 13
---

At the time of the execution of
the Merger Agreement, DiamiR, DiamiR LLC, the Company and Aptorum Therapeutics entered into the Licensing Agreement, pursuant to which
DiamiR and DiamiR LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange
for upfront and periodic payments and royalties until the earlier of the closing of the Merger or December 31, 2025.

Voting and Support Agreement

Ian
Huen, our Chairman and CEO, who beneficially owns 87.17% of the Company’s total voting power as of the date of the Merger Agreement,
signed a voting and support agreement simultaneously with the execution of the Merger Agreement, pursuant to which he agreed to vote in
favor of the transactions contemplated in the Merger Agreement.

Stockholders Agreement

Upon closing of the DiamiR Merger, Aptorum and certain stockholders
of DiamiR, who collectively own 84.9% of DiamiR’s outstanding shares, will sign a stockholders agreement (“Stockholders Agreement”),
which will be effective so long as the stockholders of DiamiR beneficially own, in the aggregate, a number of shares of common stock of
the Combined Company equal to at least 25% of the then outstanding shares of the Combined Company (such beneficial ownership, the “DiamiR
Stockholders Beneficial Ownership”; such period, the “Appointment Period”). The parties agree that, during the Appointment
Period, they will take all necessary actions to cause the number of directors at the Board of the Combined Company to be fixed at five
(5). In addition, Kira S. Sheinerman, the co-founder and a stockholder of DiamiR, and her affiliates (“DiamiR Primary Stockholder
Parties”) will have the right to appoint two (2) designees (each designee, the “Primary Stockholder Designee”,
collectively, the “Primary Stockholder Designees”) for nomination and election to the Board of Combined Company, and at least
one (1) designee shall satisfy the independence requirements of Rule 5605(c)(2)(A) of the Nasdaq listing rules, provided
that the DiamiR Stockholders Beneficial Ownership is not less than 36%, and the DiamiR Primary Stockholder Parties will have the right
to appoint one (1) director nominee to the Board of Combined Company, provided that the DiamiR Stock